BR112016026140A2 - formulações de concentrado líquido de ciclofosfamida. - Google Patents
formulações de concentrado líquido de ciclofosfamida.Info
- Publication number
- BR112016026140A2 BR112016026140A2 BR112016026140A BR112016026140A BR112016026140A2 BR 112016026140 A2 BR112016026140 A2 BR 112016026140A2 BR 112016026140 A BR112016026140 A BR 112016026140A BR 112016026140 A BR112016026140 A BR 112016026140A BR 112016026140 A2 BR112016026140 A2 BR 112016026140A2
- Authority
- BR
- Brazil
- Prior art keywords
- cyclophosphamide
- liquid concentrate
- concentrate formulations
- formulations
- liquid
- Prior art date
Links
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 title 1
- 229960004397 cyclophosphamide Drugs 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 235000014666 liquid concentrate Nutrition 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/664—Amides of phosphorus acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461991247P | 2014-05-09 | 2014-05-09 | |
| PCT/US2015/028862 WO2015171460A2 (en) | 2014-05-09 | 2015-05-01 | Formulations of cyclophosphamide liquid concentrate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112016026140A2 true BR112016026140A2 (pt) | 2018-08-07 |
Family
ID=54366856
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016026140A BR112016026140A2 (pt) | 2014-05-09 | 2015-05-01 | formulações de concentrado líquido de ciclofosfamida. |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20150320774A1 (enExample) |
| EP (1) | EP3139929A4 (enExample) |
| JP (1) | JP6516831B2 (enExample) |
| KR (1) | KR20170008252A (enExample) |
| CN (1) | CN106456654A (enExample) |
| AU (1) | AU2015256331B2 (enExample) |
| BR (1) | BR112016026140A2 (enExample) |
| CA (1) | CA2948148C (enExample) |
| RU (1) | RU2016147362A (enExample) |
| WO (1) | WO2015171460A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016005962A2 (en) | 2014-07-11 | 2016-01-14 | Dr. Reddy’S Laboratories Limited | Stable liquid formulations of cyclophosphamide and processes |
| WO2016132270A1 (en) * | 2015-02-16 | 2016-08-25 | Leiutis Pharmaceuticals Pvt Ltd | Stable ready to use cyclophosphamide liquid formulations |
| US12453737B2 (en) | 2018-08-03 | 2025-10-28 | Sinotherapeutics Inc. | Method for hydrating lyophilized cyclophosphamide composition and product thereof |
| WO2020178725A1 (en) * | 2019-03-04 | 2020-09-10 | Alembic Pharmaceuticals Limited | Stable liquid composition of cyclophosphamide |
| CA3145796A1 (en) | 2019-07-10 | 2021-01-14 | Intas Pharmaceuticals Ltd. | Stable oral composition of cyclophosphamide |
| WO2021009595A1 (en) * | 2019-07-15 | 2021-01-21 | Hetero Healthcare Limited | Cyclophosphamide injectable composition and methods for producing same |
| US20230310468A1 (en) | 2020-08-17 | 2023-10-05 | Sandoz Ag | Parenteral pharmaceutical composition comprising cyclophosphamide and a mixture of liquids |
| US11931370B2 (en) | 2021-10-08 | 2024-03-19 | Slayback Pharma Llc | Stable pharmaceutical compositions of cyclophosphamide |
| EP4226926A1 (en) | 2022-02-14 | 2023-08-16 | Extrovis AG | Stable ready-to-dilute pharmaceutical formulation comprising cyclophosphamide |
| WO2024112860A1 (en) * | 2022-11-22 | 2024-05-30 | Navinta, Llc | Novel solution formulation of cyclophosphamide |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL99688C (enExample) | 1956-12-20 | |||
| ATE66609T1 (de) * | 1986-07-11 | 1991-09-15 | Asta Pharma Ag | Loesungen von oxazaphosphorinen mit verbesserter stabilitaet und verfahren zu deren herstellung. |
| US4879286A (en) | 1987-01-28 | 1989-11-07 | Lyphomed, Inc. | Cyclophosphamide |
| US5036060A (en) * | 1988-07-25 | 1991-07-30 | Fujisawa Usa, Inc. | Cyclophosphamide |
| CA2039742A1 (en) * | 1990-04-23 | 1991-10-24 | Andrew B. Dennis | Tablet composition and method for problem pharmaceutical materials |
| AU1555099A (en) * | 1997-10-13 | 1999-05-03 | Stada Arzneimittel A.G. | Liquid presentations of oxazaphosphorine-containing pharmaceutical products |
| US6811788B2 (en) * | 2000-01-19 | 2004-11-02 | Baofa Yu | Combinations and methods for treating neoplasms |
| AUPQ849900A0 (en) * | 2000-06-30 | 2000-07-27 | Dbl Australia Pty Ltd. | Injectable composition |
| DE602005027727D1 (de) * | 2004-10-15 | 2011-06-09 | Seo Hong Yoo | Zusammensetzungen zur verringerung der toxizität von cisplatin, carboplatin und oxaliplatin |
| US8436190B2 (en) | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
| US7872050B2 (en) | 2005-03-14 | 2011-01-18 | Yaupon Therapeutics Inc. | Stabilized compositions of volatile alkylating agents and methods of using thereof |
| CN1923280A (zh) * | 2005-08-30 | 2007-03-07 | 孔庆忠 | 一种含双氯乙胺类药物的抗癌缓释注射剂 |
| JP5318403B2 (ja) * | 2007-11-30 | 2013-10-16 | 株式会社Ｓｏｋｕｄｏ | 基板処理装置 |
| US8278220B2 (en) * | 2008-08-08 | 2012-10-02 | Fei Company | Method to direct pattern metals on a substrate |
| EP2350649A4 (en) * | 2008-11-28 | 2012-11-14 | Abbott Lab | STABLE ANTIBODY COMPOSITIONS AND METHODS FOR STABILIZING THE SAME |
| KR20120052937A (ko) * | 2009-06-18 | 2012-05-24 | 아보트 러보러터리즈 | 안정한 나노입자형 약물 현탁액 |
| US20140005148A1 (en) * | 2012-06-29 | 2014-01-02 | Coldstream Laboratories Inc. | Stable liquid formulations of nitrogen mustards |
| WO2014068585A1 (en) * | 2012-10-29 | 2014-05-08 | Leiutis Pharmaceuticals Pvt. Ltd. | Novel lyophilized compositions of cyclophosphamide |
-
2015
- 2015-05-01 US US14/702,287 patent/US20150320774A1/en not_active Abandoned
- 2015-05-01 CN CN201580023235.5A patent/CN106456654A/zh active Pending
- 2015-05-01 US US14/702,320 patent/US9662342B2/en active Active
- 2015-05-01 BR BR112016026140A patent/BR112016026140A2/pt active Search and Examination
- 2015-05-01 KR KR1020167034447A patent/KR20170008252A/ko not_active Ceased
- 2015-05-01 RU RU2016147362A patent/RU2016147362A/ru unknown
- 2015-05-01 CA CA2948148A patent/CA2948148C/en active Active
- 2015-05-01 WO PCT/US2015/028862 patent/WO2015171460A2/en not_active Ceased
- 2015-05-01 EP EP15789798.4A patent/EP3139929A4/en not_active Withdrawn
- 2015-05-01 JP JP2017511153A patent/JP6516831B2/ja not_active Expired - Fee Related
- 2015-05-01 AU AU2015256331A patent/AU2015256331B2/en not_active Ceased
-
2017
- 2017-04-28 US US15/581,134 patent/US20170232015A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US9662342B2 (en) | 2017-05-30 |
| RU2016147362A (ru) | 2018-06-13 |
| RU2016147362A3 (enExample) | 2018-10-01 |
| JP6516831B2 (ja) | 2019-05-22 |
| CN106456654A (zh) | 2017-02-22 |
| US20150320774A1 (en) | 2015-11-12 |
| WO2015171460A2 (en) | 2015-11-12 |
| KR20170008252A (ko) | 2017-01-23 |
| US20170232015A1 (en) | 2017-08-17 |
| AU2015256331B2 (en) | 2020-03-12 |
| CA2948148C (en) | 2022-12-06 |
| AU2015256331A1 (en) | 2016-11-17 |
| EP3139929A2 (en) | 2017-03-15 |
| CA2948148A1 (en) | 2015-11-12 |
| JP2017514924A (ja) | 2017-06-08 |
| US20150320775A1 (en) | 2015-11-12 |
| EP3139929A4 (en) | 2018-01-03 |
| WO2015171460A3 (en) | 2016-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FIC20230006I1 (fi) | Vutrisiraani | |
| LT3230281T (lt) | 1,3-tiazol-2-ilu pakeisti benzamidai | |
| DK3224340T3 (da) | Ølkoncentrat | |
| DK3236749T3 (da) | Flydende tribenuron-holdige herbicidsammensætninger | |
| BR112016023628A2 (pt) | composições farmacêuticas. | |
| CL2016002657A1 (es) | Compuestos de diaminotriazina como herbicidas. | |
| BR112016026140A2 (pt) | formulações de concentrado líquido de ciclofosfamida. | |
| BR112016022040A2 (pt) | aparelho de fixação. | |
| BR112017001387A2 (pt) | alargador. | |
| BR112016020077A2 (pt) | composições de lactase líquida | |
| FR3023988B3 (fr) | . | |
| BR112017001389A2 (pt) | alargador. | |
| CL2015001228S1 (es) | Dispensador de bebidas. | |
| BR112017001388A2 (pt) | alargador. | |
| BR112017001386A2 (pt) | alargador. | |
| CL2016002165A1 (es) | Compuestos de aminocarbonilcarbamato | |
| BR112017013156A2 (pt) | combinações de composto ativo. | |
| ES1150114Y (es) | Abarcón. | |
| BR112017012801A2 (pt) | combinações de composto ativo. | |
| CL2014002647S1 (es) | Contenedor. | |
| BR112016017925A2 (pt) | Formulação de colagem estabilizada | |
| BR112016025075A2 (pt) | formulação agroquímica. | |
| BR112016027580A2 (pt) | Formulação de ceritinib | |
| ZA201806530B (en) | Phosphaplatin liquid formulations | |
| BR112016018071A2 (pt) | composição de larvicida. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B11D | Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time |